Search
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by
Benzoctamine
go.drugbank.com/drugs/DB09021ExperimentalIt can be used as a sedative which does not depress the respiratory system, but rather stimulates it.
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Tolevamer
go.drugbank.com/drugs/DB01344ApprovedIt may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedApproved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label]. … Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment
Meningococcal polysaccharide vaccine group Y
go.drugbank.com/drugs/DB13888ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.